# Caribou Biosciences, Inc.: overview CRBU · Nasdaq · CIK 1619856 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/crbu.md) · [Financials](/companies/crbu/financials.md) · [Filings](/companies/crbu/filings.md) · [Insiders](/companies/crbu/insiders.md) Latest reported revenue: [$1.5m](/filings/0001619856-26-000055.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001619856-26-000055). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [2.0](/filings/0001619856-25-000071.md) | [2.1 d](/filings/0001619856-26-000008.md) | [2.4](/filings/0001619856-26-000036.md) | [2.7](/filings/0001619856-26-000055.md) | [2.2](/filings/0001619856-25-000071.md) | [3.9 d](/filings/0001619856-26-000008.md) | [2.4](/filings/0001619856-26-000036.md) | [1.5](/filings/0001619856-26-000055.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(1889.2%)](/filings/0001619856-25-000071.md) | [(1871.7%) d](/filings/0001619856-26-000008.md) | [(1823.8%)](/filings/0001619856-26-000036.md) | [(1784.0%)](/filings/0001619856-26-000055.md) | [(1337.6%)](/filings/0001619856-25-000071.md) | [(722.0%) d](/filings/0001619856-26-000008.md) | [(1096.4%)](/filings/0001619856-26-000036.md) | [(1690.4%)](/filings/0001619856-26-000055.md) | | Net margin | % | [(1713.6%)](/filings/0001619856-25-000071.md) | [(1708.7%) d](/filings/0001619856-26-000008.md) | [(1699.6%)](/filings/0001619856-26-000055.md) | [(2028.4%)](/filings/0001619856-26-000055.md) | [(1253.3%)](/filings/0001619856-25-000071.md) | [(672.1%) d](/filings/0001619856-26-000008.md) | [(1046.5%)](/filings/0001619856-26-000055.md) | [(1619.9%)](/filings/0001619856-26-000055.md) | | Diluted EPS | $ per share | [(0.38)](/filings/0001619856-25-000071.md) | not reported | [(0.43)](/filings/0001619856-26-000036.md) | [(0.58)](/filings/0001619856-26-000055.md) | [(0.30)](/filings/0001619856-25-000071.md) | not reported | [(0.26)](/filings/0001619856-26-000036.md) | [(0.24)](/filings/0001619856-26-000055.md) | | Free cash flow | $m | [(33.3) d](/filings/0001619856-25-000071.md) | [(36.0) d](/filings/0001619856-26-000008.md) | [(37.8)](/filings/0001619856-26-000036.md) | [(28.7) d](/filings/0001619856-26-000055.md) | [(25.3) d](/filings/0001619856-25-000071.md) | [(21.0) d](/filings/0001619856-26-000008.md) | [(27.1)](/filings/0001619856-26-000036.md) | [(22.8) d](/filings/0001619856-26-000055.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [9.6](/filings/0001619856-23-000037.md) | [13.9](/filings/0001619856-24-000013.md) | [34.5](/filings/0001619856-25-000015.md) | [10.0](/filings/0001619856-26-000008.md) | [11.2](/filings/0001619856-26-000008.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(697.8%)](/filings/0001619856-23-000037.md) | [(768.2%)](/filings/0001619856-24-000013.md) | [(336.6%)](/filings/0001619856-25-000015.md) | [(1667.2%)](/filings/0001619856-26-000008.md) | [(1329.4%)](/filings/0001619856-26-000008.md) | | Net margin | % | [(697.3%)](/filings/0001619856-23-000037.md) | [(717.8%)](/filings/0001619856-24-000013.md) | [(296.1%)](/filings/0001619856-25-000015.md) | [(1491.9%)](/filings/0001619856-26-000008.md) | [(1327.4%)](/filings/0001619856-26-000008.md) | | Diluted EPS | $ per share | [(2.11)](/filings/0001619856-23-000037.md) | [(1.64)](/filings/0001619856-24-000013.md) | [(1.38)](/filings/0001619856-25-000015.md) | [(1.65)](/filings/0001619856-26-000008.md) | [(1.59)](/filings/0001619856-26-000008.md) | | Free cash flow | $m | [(34.6)](/filings/0001619856-23-000037.md) | [(97.4)](/filings/0001619856-24-000013.md) | [(105)](/filings/0001619856-25-000015.md) | [(143)](/filings/0001619856-26-000008.md) | [(112)](/filings/0001619856-26-000008.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/crbu/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $13.8m | 7,815,843 | | Added +5,672,758 | | [Pfizer Inc](/funds/78003.md) | 2026-06-30 | $7.9m | 4,690,431 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $7.4m | 4,208,568 | | Added +441,340 | | [MACKENZIE FINANCIAL CORP](/funds/919859.md) | 2026-06-30 | $6.4m | 3,650,796 | | Added +2,708,010 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $4.9m | 2,773,545 | | Added +183,048 | | [Kynam Capital Management, LP](/funds/1907884.md) | 2026-06-30 | $4.4m | 2,503,302 | | Unchanged | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $4.2m | 2,374,894 | | Added +1,356,935 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $2.9m | 1,632,914 | | Added +1,209,651 | | [BANK OF AMERICA CORP /DE/](/funds/70858.md) | 2026-06-30 | $2.5m | 1,410,958 | | Added +113,791 | | [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $1.8m | 1,046,279 | | Reduced −713,655 | ## Recent filings [All 305 filings](/companies/crbu/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-06 | 20:07 ET | [8-K](/filings/0001193125-26-415559.md) | 2.05 Exit or disposal costs; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-415559 | | 2026-08-13 | 20:11 ET | [10-Q](/filings/0001619856-26-000055.md) | Quarterly report, period 2026-06-30 | 0001619856-26-000055 | | 2026-08-13 | 20:07 ET | [8-K](/filings/0001619856-26-000053.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001619856-26-000053 | | 2026-06-18 | 20:02 ET | [8-K](/filings/0001619856-26-000047.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001619856-26-000047 | | 2026-06-11 | 12:02 ET | [8-K](/filings/0001619856-26-000043.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001619856-26-000043 | | 2026-05-07 | 20:14 ET | [10-Q](/filings/0001619856-26-000036.md) | Quarterly report, period 2026-03-31 | 0001619856-26-000036 | | 2026-05-07 | 20:10 ET | [8-K](/filings/0001619856-26-000035.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001619856-26-000035 | | 2026-04-24 | 20:01 ET | [DEF 14A](/filings/0001619856-26-000022.md) | Proxy statement, period 2025-12-31 | 0001619856-26-000022 | | 2026-03-31 | 12:02 ET | [8-K](/filings/0001619856-26-000012.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001619856-26-000012 | | 2026-03-05 | 21:09 ET | [10-K](/filings/0001619856-26-000008.md) | Annual report, period 2025-12-31 | 0001619856-26-000008 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001619856-26-000008.md), filed Mar 5, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/772a6d7a-8ed9-4a1c-9511-228c9dbc5b4d) ## About the filer - CIK: 1619856 - Tickers: CRBU - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.